- Home
- MEOH vs RCUS Comparison
MEOH vs RCUS Comparison
Compare MEOH & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MEOH | RCUS |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MEOH | RCUS |
|---|---|---|
| Price | $54.38 | $28.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $58.33 | $31.90 |
| AVG Volume (30 Days) | ★ 998.9K | 995.6K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $25.43 | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | $16.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.00 | $8.88 |
| 52 Week High | $66.75 | $31.74 |
Technical Indicators
Market Signals| Indicator | MEOH | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout MEOH Methanex Corporation
Methanex Corp operates as a producer and supplier of methanol to various international markets in North America, Asia Pacific, Europe and South America. The company's operations consist prominently of the production and sale of methanol, along with the production and sale of ammonia. Geographically, it operates in China, Europe, the United States, South America, South Korea, Other Asia, and Canada. The majority of revenue is derived from Europe.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.